深圳市新产业生物医学工程股份有限公司 2024 年度董事会工作报告 2024 年，深圳市新产业生物医学工程股份有限公司（以下简称"公司"） 董事会严格按照《公司法》《证券法》等法律法规、规范性文件以及《公司章程》 《公司董事会议事规则》等规章制度的规定，本着对股东负责的态度，恪尽职守、 积极有效地行使职权，认真贯彻落实股东会的各项决议，勤勉尽责地开展董事会 各项工作，不断提高公司的治理水平，促进公司规范运作，保证了公司持续、健 康、稳定的发展。现将 2024 年度公司董事会工作情况汇报如下： 一、 2024 年公司经营情况 参阅公司 2024 年年度报告第三节管理层讨论与分析部分。 二、 2024 年公司董事会工作情况 （一）董事会会议召开情况 2024 年，公司董事会充分发挥董事会在公司治理体系中的作用，共组织召 开 5 次董事会会议，会议的召集与召开程序、出席会议人员的资格、会议表决程 序、表决结果和决议内容均符合《公司法》《公司章程》和《公司董事会议事规 则》的有关规定。具体内容如下： | 序号 | 日期 | 会议名称 | 审议事项 | | --- | --- | --- | --- | | 1 | 2 ...

证券代码：300832 证券简称：新产业 公告编号：2025-032 深圳市新产业生物医学工程股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第五届董事会第三次会议、第五届监事会第三次会议审议通过了《关 于使用闲置自有资金购买理财产品的议案》，为进一步提高公司自有资金使用效 率，增加公司现金资产收益，并确保资金安全、操作合法合规，在不影响公司正 常生产经营的基础上，公司拟使用最高额度不超过 45 亿元的闲置自有资金购买 安全性高、流动性好、投资回报相对较好的理财产品，以上资金额度在决议有效 期内可以滚动使用。公司董事会同意授权公司总经理在额度范围内行使该项投资 决策权并签署相关合同文件，决议有效期为公司股东会审议通过该议案之日起 1 年内有效。具体情况如下： 一、 投资情况概述 (一) 投资目的 在确保资金安全、操作合法合规、保证日常经营不受影响的前提下，利用闲 置自有资金购买理财产品，有利于充分利用公司自有资金， ...

证券代码：300832 证券简称：新产业 公告编号：2025-037 深圳市新产业生物医学工程股份有限公司 关于召开 2024 年年度股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开的第五届董事会第三次会议审议通过了《关于提请召开深圳市新 产业生物医学工程股份有限公司 2024 年年度股东会的议案》，决定于 2025 年 5 月 19 日（星期一）下午 14:30 以现场投票结合网络投票的方式召开公司 2024 年 年度股东会（以下简称"本次股东会"），现将本次股东会的有关事项通知如下： 一、召开会议基本情况 1、股东会届次：2024 年年度股东会。 2、会议召集人：公司第五届董事会。第五届董事会第三次会议审议通过了 《关于提请召开深圳市新产业生物医学工程股份有限公司 2024 年年度股东会的 议案》，会议决定于 2025 年 5 月 19 日以现场投票结合网络投票的方式召开公司 本次股东会。 3、会议召开的合法、合规性：本次股东会召集程序符合有关法律、 ...

证券代码：300832 证券简称：新产业 公告编号：2025-024 深圳市新产业生物医学工程股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1. 本次监事会会议通知已于 2025 年 4 月 15 日以电子邮件方式送达各位监 事。 2. 本次监事会于 2025 年 4 月 25 日上午 11:00 以现场表决的方式召开，现 场会议地址为深圳市坪山区坑梓街道锦绣东路 23 号新产业生物大厦 21 楼 2104 会议室。 3. 本次监事会应出席监事 3 名，实际出席监事 3 名；没有监事委托其他监 事代为出席或缺席本次会议，与会监事以记名投票表决方式对会议审议议案进行 了表决。 4. 本次会议由监事会主席刘登科主持。 5. 经全体与会监事确认，本次会议的召集、召开以及审议程序符合《公司 法》《公司章程》和《公司监事会议事规则》等有关规定，会议形成的决议合法、 有效。 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： (一)审议并通过《关于 2024 年度监事 ...

1.本次董事会会议通知已于 2025 年 4 月 15 日以电子邮件方式送达各位董 事。 2.本次董事会于 2025 年 4 月 25 日上午 10:00 以现场表决的方式召开，现场 会议地址为深圳市坪山区坑梓街道锦绣东路 23 号新产业生物大厦 21 楼董事会 议室。 3.本次董事会应出席董事 7 名，实际出席董事 7 名；没有董事委托其他董事 代为出席或缺席本次会议，与会董事以记名投票表决方式对会议审议议案进行了 表决。 4.本次会议由董事长饶微主持，部分公司监事和高级管理人员列席会议。 证券代码：300832 证券简称：新产业 公告编号：2025-023 深圳市新产业生物医学工程股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 经全体与会董事认真审议、充分讨论，会议审议并通过了以下议案： (一) 审议并通过《关于 2024 年度总经理工作报告的议案》 审议通过的内容如下： 董事会听取了总经理饶微先生所作的《2024 年度总经理工作报告》，认为 2024 年度公司经营管理层有效执行了股东 ...

证券代码：300832 证券简称：新产业 公告编号：2025-029 深圳市新产业生物医学工程股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开了第五届董事会第三次会议、第五届监事会第三次会议，审议通过 了《关于公司 2024 年度利润分配预案的议案》，具体情况如下： 一、2024 年度利润分配预案基本情况 根据政旦致远（深圳）会计师事务所（特殊普通合伙）出具的政旦志远审字 第 2500096 号《审计报告》，公司 2024 年度实现母公司净利润及合并报表归属于 上市公司股东的净利润分别为 1,818,159,813.63 元和 1,828,456,618.27 元。截止 2024 年 12 月 31 日，母公司报表及合并报表中的期末可供分配的利润分别为 6,035,899,031.53 元和 6,023,930,355.60 元。 结合公司资金状况和所处的发展阶段，为积极回报股东，董事会拟定了 2024 年度利润分 ...

新产业（300832）公告，2024年营业收入为45.35亿元，同比增长15.41%。归属于上市公司股东的净利 润18.28亿元，同比增长10.57%。基本每股收益2.33元/股，同比增长10.53%。公司拟向全体股东每10股 派发现金红利13元(含税)。 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,124,761,573, representing a 10.12% increase compared to CNY 1,021,430,175 in the same period last year[4] - Net profit attributable to shareholders was CNY 437,511,949, a 2.65% increase from CNY 426,221,044 in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 416,658,656, up 4.39% from CNY 399,135,667 in the same period last year[4] - The company's weighted average return on equity decreased by 0.52 percentage points to 4.97% from 5.49% in the previous year[4] - The company achieved operating revenue of RMB 1,124.76 million, representing a year-on-year growth of 10.12%[17] - Domestic main business revenue grew by 0.11% year-on-year, while overseas main business revenue increased by 27.03%[17] - Total operating revenue for the current period reached ¥1,124,761,573, an increase of 10.1% compared to ¥1,021,430,174.73 in the previous period[23] - Net profit for the current period was ¥437,511,949.25, reflecting a slight increase of 2.9% from ¥426,221,043.84 in the previous period[24] - Basic and diluted earnings per share improved to ¥0.5568, compared to ¥0.5425 in the prior period[25] Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline, with a net cash flow of CNY 18,542,686, down 92.92% from CNY 261,740,278 in the previous year[10] - Cash flow from operating activities saw a significant decline due to a delay in accounts payable payments, which will be concentrated in January 2025[17] - The company's cash and cash equivalents decreased to RMB 651.09 million from RMB 919.53 million[18] - The net cash flow from operating activities was $18,542,685.84, a significant decrease of 92.9% compared to $261,740,277.69 in the previous period[26] - Cash outflow from operating activities totaled $987,541,010.85, up 42.6% from $692,205,163.45 in the prior period[26] - The ending balance of cash and cash equivalents was $651,087,913.23, down 36.6% from $1,027,068,268.06 at the end of the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,729,267,086, reflecting a 1.14% increase from CNY 9,619,453,527 at the end of the previous year[4] - The equity attributable to shareholders increased by 4.98% to CNY 9,003,866,643 from CNY 8,576,607,475 at the end of the previous year[4] - Total liabilities decreased to ¥725,400,442.96 from ¥1,042,846,052.20, indicating a reduction of approximately 30.4%[21] - The total liabilities and equity amounted to ¥9,729,267,085.68, up from ¥9,619,453,527.11, reflecting a growth of 1.1%[21] Operating Costs and Profitability - The company's gross profit margin decreased, with operating costs rising by 34.61% to CNY 359,759,645 due to increased sales volume of large instruments[9] - Total operating costs amounted to ¥643,259,211.97, up 15.1% from ¥558,596,850.28 in the prior period, with operating costs specifically rising from ¥267,255,498.99 to ¥359,759,644.98[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,269[12] Government Support - The company received government subsidies amounting to CNY 15,265,086, a 125.88% increase compared to CNY 6,758,014 in the previous year[9] Research and Development - Research and development expenses remained stable at ¥101,897,244.82, slightly increasing from ¥101,455,514.48[24] Other Financial Activities - The company reported a significant increase in its debt investment, rising to RMB 1,868.42 million from RMB 1,778.96 million[19] - The company plans to upgrade its ERP system by the end of 2024, which may impact payment processes[17] - Other comprehensive income after tax decreased to -¥10,252,781.44 from -¥6,112,114.04, indicating a decline in this area[24] - The net cash flow from investing activities was -$295,543,409.68, worsening from -$277,676,044.43 in the previous period[26] - The total cash outflow from investing activities was $1,032,671,858.93, a decrease of 45.4% from $1,887,962,302.77[26] Audit Information - The company did not undergo an audit for the first quarter report[28]

Financial Performance - The company's operating revenue for 2024 reached ¥4,535,404,459.13, representing a 15.41% increase compared to ¥3,929,655,726.27 in 2023[15]. - The net profit attributable to shareholders for 2024 was ¥1,828,456,618.27, up 10.57% from ¥1,653,653,244.98 in 2023[15]. - The net profit after deducting non-recurring gains and losses was ¥1,720,490,659.23, an increase of 11.19% from ¥1,547,315,497.48 in 2023[15]. - The total assets at the end of 2024 amounted to ¥9,619,453,527.11, reflecting a 16.99% growth from ¥8,222,488,843.69 at the end of 2023[15]. - The net assets attributable to shareholders increased by 13.68% to ¥8,576,607,474.91 at the end of 2024, compared to ¥7,544,400,237.20 at the end of 2023[15]. - The company reported a decrease in cash flow from operating activities, with a net cash flow of ¥1,356,439,053.53, down 4.36% from ¥1,418,292,417.91 in 2023[15]. - The company reported a basic earnings per share of ¥2.3271 for 2024, a 10.53% increase from ¥2.1054 in 2023[15]. - The overall revenue for the reporting period reached 4.535 billion yuan, a growth of 15.41% compared to the previous year[56]. - The gross profit margin for the company was 72.26%, with the instrument gross profit margin increasing to 29.82%[56]. - The company's overseas business achieved a main operating income of 1.684 billion yuan, a year-on-year increase of 27.67%[54]. Market and Industry Insights - The global in vitro diagnostic market is projected to reach $109.2 billion in 2024, with a compound annual growth rate of 4.3% from 2024 to 2029[24]. - The Chinese in vitro diagnostic market size was approximately ¥998.13 billion in 2023, driven by policy support and increasing market demand[26]. - The domestic in vitro diagnostic market is experiencing rapid growth due to the shift in medical consumption concepts and the aging population, with significant potential for market expansion[128]. - The domestic immunodiagnostics market reached 37.52 billion RMB in 2023, accounting for 37.59% of the total in vitro diagnostics market, with multinational companies holding 71.2% market share[27]. - The immunodiagnostics market experienced a growth rate of 13% in 2023, driven by a rebound in diagnostic volumes and the recovery of routine testing demand[27]. - The domestic biochemical diagnostics market was valued at 11.15 billion RMB in 2023, with a year-on-year growth of 5%, and local manufacturers increasing their procurement ratio in hospitals[27]. Product Development and Innovation - The company has developed 224 types of chemical luminescence immunoassays, with 198 having obtained EU market access, making it one of the most comprehensive suppliers in the industry[32]. - The company launched the high-throughput MAGLUMI X10 in early 2024, enhancing efficiency for medical terminals[149]. - The company has established four major technology platforms for in vitro diagnostic product development, including nano magnetic microspheres, key reagent raw materials, fully automated diagnostic instruments, and diagnostic reagents[38]. - The company has developed innovative products such as the Molecision R8 and MAGLUMI X10, which feature high throughput and advanced contamination prevention technologies[67][68]. - The company is focusing on product line strategic planning and enhancing project reliability and compliance in instrument development[66]. Corporate Governance and Investor Relations - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[154]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[157]. - The company emphasizes independent operations, with no interference from the controlling shareholder in decision-making or business activities[156]. - The company has a performance evaluation and incentive mechanism for senior management directly linked to operational performance, overseen by the remuneration and assessment committee[160]. - The company actively engages with stakeholders to balance interests and promote sustainable development[161]. - The company is committed to transparency and regular communication with investors, as evidenced by its detailed activity records shared on the 巨潮资讯网 platform[142][143]. Risk Management - The company has a comprehensive risk management strategy outlined in the report, detailing potential risks and countermeasures[3]. - The company has established a comprehensive risk management framework for its foreign exchange hedging activities to mitigate potential risks[121]. - The company is aware of the risks associated with new product development, including potential delays and regulatory challenges, and is enhancing its pre-research and market analysis efforts[134][135]. Employee and Management Insights - The total number of employees at the end of the reporting period is 2,841, including 2,816 from the parent company and 25 from major subsidiaries[200]. - The company has 898 production personnel, 545 sales personnel, 348 technical personnel, and 836 R&D personnel, indicating a strong focus on research and development[200]. - The educational background of employees includes 9 with PhDs, 552 with master's degrees, and 1,499 with bachelor's degrees, reflecting a highly educated workforce[200]. Cash Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 13 RMB for every 10 shares, totaling approximately 1,021,434,420.50 RMB, which represents 55.86% of the net profit attributable to shareholders for the year 2024[152]. - The company has maintained a dividend payout ratio above 40% for five consecutive years from 2020 to 2024, positioning it in the upper tier of the A-share market[152]. - The company actively promotes cash dividends to enhance shareholder returns as part of its "Quality Return Dual Improvement" action plan[148].

深圳市新产业生物医学工程股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2024 年 12 月 31 日） 深圳市新产业生物医学工程股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 政旦志远核字第 2500042 号 政旦志远（深圳）会计师事务所（特殊普通合伙） Zandar Certified Public Accountants LLP 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项 说明 1-2 二、 深圳市新产业生物医学工程股份有限公司 2024 年度非经营性资金占用及其他关联资金 往来情况汇总表 1 地 址：深圳市福田区鹏程一路广电金融中心 11F 电 话：+86-755-88605026 www.zdcpa.com 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 政旦志远核字第 2500042 号 深圳市新产业生物医学工程股份有限公司全体股东： 我们接受委托，依据《中国注册会计师执业准则》审计了深圳市 新产业生物医学工程股份有限公司（以下简称新产业公司）2024 年度 财务报表，包括 2024 年 12 月 31 日的合 ...